Testing for Ns5a Resistance in Order to Optimize Antiviral Therapy With Simeprevir And Sofosbuvir 12 Weeks Appears Cost-Effective in Non-Cirrhotic Genotype 1 Hepatitis C Virus Treatment Experienced Patients

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1509
https://www.valueinhealthjournal.com/article/S1098-3015(15)03585-8/fulltext
Title : Testing for Ns5a Resistance in Order to Optimize Antiviral Therapy With Simeprevir And Sofosbuvir 12 Weeks Appears Cost-Effective in Non-Cirrhotic Genotype 1 Hepatitis C Virus Treatment Experienced Patients
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03585-8&doi=10.1016/j.jval.2015.09.1509
First page : A589
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 1410
Categories :
Tags :
Regions :
ViH Article Tags :